Cumplimiento de las recomendaciones de ajuste de la dosis de inhibidores DPP4 según la función renal en una base de datos poblacional

Davies, 2018, Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD), Diabetologia, 61, 2461, 10.1007/s00125-018-4729-5 NICE. Type 2 diabetes in adults: management, 2017 [consultado 20 Nov 2018] Disponible en: http://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493 (page 22 - Algorithm for blood glucose lowering therapy in adults with type 2 diabetes) Gómez-Huelgas, 2014, Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica, Nefrol., 34, 34 Preguntas y Respuestas sobre la información a incluir en Ficha Técnica, Etiquetado y Prospecto. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) website. Updated July 13, 2018 [consultado 17 Nov 2020] Disponible en: https://www.aemps.gob.es/industria-farmaceutica/etiquetado-y-prospectos/industria_etiquetado_preguntasrespuestas/?lang=ca Park, 2012, Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis, Ann Pharmacother, 46, 1453, 10.1345/aph.1R041 Gómez-Huelgas, 2014, Documento de consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica, Nefrología (Madr), 34, 34 Scheen, 2015, Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes, Clin Pharmacokinet, 54, 1, 10.1007/s40262-014-0198-2 Centro de información online de medicamentos de la AEMPS – CIMA website. Updated November, 16 2020 [consultado 17 Nov 2020] Disponible en: https://cima.aemps.es/cima/publico/home.html Mata-Cases, 2019, Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: A population-based cross-sectional study, BMJ Open, 9, e031281, 10.1136/bmjopen-2019-031281 Chen, 2012, Clinical and economic outcomes associated with national kidney foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease, Curr Med Res Opin, 28, 493, 10.1185/03007995.2012.658909 Mazer-Amirshahi, 2018, Advances in diabetes pharmacotherapy: An update for the emergency provider, J Emerg Med, 54, 73, 10.1016/j.jemermed.2017.08.024 Russell, 2014, Clinical effects of exposure to DPP-4 inhibitors as reported to the national poison data system, J Med Toxicol, 10, 152, 10.1007/s13181-014-0383-6 Bloomfield, 2009, A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects, J Clin Pharmacol, 49, 937, 10.1177/0091270009337511 Hong, 2020, Outcomes for inappropriate renal dose adjustment of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Population-based study, Mayo Clin Proc, 95, 101, 10.1016/j.mayocp.2019.06.010 Manski-Nankervis, 2019, Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: A national cross-sectional study, BMC Fam Pract, 20, 29, 10.1186/s12875-019-0915-x González-Juanatey, 2006, Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas, Rev Esp Cardiol, 59, 801, 10.1157/13091884 Manski-Nankervis, 2019, Prescribing for people with type 2 diabetes and renal impairment in australian general practice: A national cross sectional study, Prim Care Diabetes, 13, 113, 10.1016/j.pcd.2018.09.001 del Mar García-Gil, 2011, Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP), Inform Prim Care, 19, 135 Vinagre, 2012, Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain), Diabetes Care, 35, 774, 10.2337/dc11-1679 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 Levey, 2020, Nomenclature for kidney function and disease: Report of a kidney disease: Improving global outcomes (KDIGO) consensus conference, Kidney Int, 10.1016/j.kint.2020.02.010 2018, Purpose of the ATC/DDD system.Norwegian Institute for Public Health Concept: Dose Intensity. University of Manitoba, Rady Faculty of Health Sciences website. Updated December 01, 2004 [consultado 17 Nov 2020] Disponible en: http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?printer=Y&conceptID=1122 Kale, 2018, Overdiagnosis in primary care: Framing the problem and finding solutions, BMJ, 362, k2820, 10.1136/bmj.k2820 Ogundipe, 2020, Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: A systematic review and meta-analysis involving 594,138 patients with type 2 diabetes, Acta Diabetol, 1 Spanopoulos, 2019, DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice, Clin Ther, 41, 1622, 10.1016/j.clinthera.2019.05.010 Spanopoulos, 2018, Prescription of DPP-4 inhibitors to type 2 diabetes mellitus patients with renal impairment: A UK primary care experience, Clin Ther, 40, 152, 10.1016/j.clinthera.2017.11.009 Huang, 2018, Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease, Curr Med Res Opin, 34, 1021, 10.1080/03007995.2017.1416346 Davis, 2014, Dipeptidyl peptidase-4 inhibitors: Pharmacokinetics, efficacy, tolerability and safety in renal impairment, Diabetes Obes Metab, 16, 891, 10.1111/dom.12295 Fonseca, 2011, Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr Vivian A. Fonseca, Am J Med, 124, S54, 10.1016/j.amjmed.2010.11.005